Melbourne, Victoria, Australia
Trajan Scientific and Medical (Trajan) has been featured by @AuManufacturing, highlighting Trajan's ongoing investment into the development of hemaPEN®, and other technologies to address emerging trends in healthcare.
The article outlines Trajan's collaborative approach to R&D, and success in identifying and manufacturing niche technologies for global markets.
Read the full article at @AUManufacturing - Pens and prospering as a manufacturer.
The hemaPEN® is a device supplied for research purposes only. This device is not for therapeutic or diagnostic use.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.